Rituximab: An insider's historical perspective

Seminars in Oncology

Volumn 27, Issue 6 SUPPL. 12, 2000, Pages 9-16

  Grillo Lopez A J ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; INTERFERON; MONOCLONAL ANTIBODY; ORTHOCLONE; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; YTTRIUM 90;

BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HISTORY, 20TH CENTURY; HUMANS; LYMPHOMA, NON-HODGKIN;

EID: 0034468346     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Antibodies as cytotoxic therapy
2. Overview of the clinical development of Rituximab: First monoclonal antibody approved for the treatment of lymphoma
3. Rituximab: The first monoclonal antibody approved for the treatment of lymphoma
4. Preclinical studies, mechanism of action, and development of rituximab
5. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
6. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs
7. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
8. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
9. Pilot efficacy studies of rituximab in combination with chemotherapy, biologicals, or radioimmunotherapy
10. Rituximab in indolent lymphoma: The single-agent pivotal trial
11. Lymphocyte depletion during treatment with intensive chemotherapy for cancer
12. Autologous bone-marrow transplantation in non-Hodgkin's lymphomas
13. Clearance of bcl-2 (t14;18) from peripheral blood and bone marrow in patients with relapsed low-grade or follicular lymphoma following single agent therapy with the chimeric anti-CD20 antibody IDEC-C2B8
14. Rituximab clearance of bcl-2 from peripheral blood (PB) and bone marrow (BM) from patients (PTS) with relapsed low-grade follicular lymphoma (LG/F NHL)
15. Association of serum rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma
16. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
17. Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma
18. Rituximab: Correlation between effector cells and clinical activity in NHL
19. Chimeric anti-CD20 monoclonal antibody (rituximab) plus G-CSF in relapsed B-cell lymphoma: A phase I/II clinical trial
20. Differences in CD20- and HLA-DR-Antibody dependent cellular cytotoxicity in B cells mediated by G-CSF-stimulated neutrophils
21. Interferon-g (IFN-g) induces CD20 expression on multiple myeloma (MM) patient and healthy donor (HD) plasma cells and B-cells and augments binding of rituximab (Rituxan) to MM plasma cells
22. Rituxan (R)-induced apoptosis in DHL-4 cells can be augmented by priming interferon-alpha (IFN)
23. Rituximab monoclonal antibody as initial therapy for patients with low-grade non-Hodgkin's lymphoma
24. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion
25. Phase I study of IDEC-Y2B8: 90-Yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma
26. Prospective randomized controlled study of Zevalin (IDEC-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: Report of interim results
27. In vivo purging with rituximab during stem cell transplantation for indolent lymphoma
28. Rituxan in the treatment of cold agglutinin disease